Pam S. Dellea

The Lifetime Medical Cost Burden of Overweight and Obesity: Implications for Obesity Prevention

Eric Finkelstein, Justin G. Trogdon, Derek S. Brown et al. · Obesity · 2008 · 173 citations

Obesity Prevention Efforts, Lifetime Costs, Financial Protection +21

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

Anselm K. Gitt, Heinz Drexel, J. Feely et al. · European Journal of Preventive Cardiology · 2011 · 163 citations · Full text

Orally Active .beta.-Lactam Inhibitors of Human Leukocyte Elastase. 3. Stereospecific Synthesis and Structure-Activity Relationships for 3,3-Dialkylazetidin-2-ones

P E Finke, S. K. Shah, D. Fletcher et al. · Journal of Medicinal Chemistry · 1995 · 89 citations · Full text

A Comparison of α ₁ -Proteinase Inhibitor Methoxysuccinyl-Ala-Ala-Pro-Val-Chloromethylketone and Specific β-Lactam Inhibitors in an Acute Model of Human Polymorphonuclear Leukocyte Elastase-induced Lung Hemorrhage in the Hamster

Daniel S. Fletcher, Donald G. Osinga, Karen M. Hand et al. · American Review of Respiratory Disease · 1990 · 44 citations

Pharmacological profile of the substituted beta‐lactam L‐659,286: A member of a new class of human PMN elastase inhibitors

Robert J. Bonney, Bonnie M. Ashe, Alan L. Maycock et al. · Journal of Cellular Biochemistry · 1989 · 30 citations